Medicine
Abrilada kit
Abrilada kit is a prescription medicine containing Adalimumab, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store in original carton until time of administration to protect from light.
Key facts
- Active ingredient (INN)
- Adalimumab
- Brand
- Abrilada
- Dosage form
- Kit
- Packs
- 1 kit, 2 kits and 3 more
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturers
- Pfizer LaboratoriesA-S Medication Solutions
- Origin register
- US FDA, United States
- Storage
- Store in original carton until time of administration to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AB04 Adalimumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 14 December 2023
- Identifiers
- RxCUI 797544, 2668074, 2668078 +7DailyMed set ID 1602cfaf-9ddd-4eb6-b847-10a4eebcf5e5, 79943fe6-1249-4074-9aed-c53937820d0f, 5ef1c7cf-466f-495e-8d13-82e2ddfa7a4fNDC 50090-8032, 50090-7998, 0025-0328 +2Application BLA761118
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton / 1 kit in 1 kit * .8 mL in 1 syringe * 1 mL in 1 packet | 0025-0325-01 | Pfizer Laboratories | 14 December 2023 |
| 2 kit in 1 carton / 1 kit in 1 kit * .8 mL in 1 syringe * 1 mL in 1 packet | 0025-0325-02 | Pfizer Laboratories | 14 December 2023 |
| 2 kit in 1 carton / 1 kit in 1 kit * 1 syringe in 1 tray / .8 mL in 1 syringe * 1 mL in 1 packet | 0025-0328-02 | Pfizer Laboratories | 14 December 2023 |
| 2 kit in 1 carton / 1 kit in 1 kit * 1 syringe in 1 tray / .4 mL in 1 syringe * 1 mL in 1 packet | 0025-0333-02 | Pfizer Laboratories | 14 December 2023 |
| 2 kit in 1 carton / 1 kit in 1 kit * .8 mL in 1 syringe * 1 mL in 1 packet | 50090-7998-0 | A-S Medication Solutions | 17 June 2026 |
| 1 kit in 1 kit * 1 syringe in 1 tray / .8 mL in 1 syringe * 1 mL in 1 packet | 50090-8032-0 | A-S Medication Solutions | 5 August 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Adalimumab kit.
- Adalimumab kitAvailable on request—US FDA36 packs Cold chain
- Humira kitAvailable on requestAbbVieUS FDA19 packs Cold chain
- Adalimumab kitAvailable on request—US FDA6 packs Cold chain
- Cyltezo kitAvailable on requestBoehringer Ingelheim PharmaceuticalsUS FDA6 packs Cold chain
- Simlandi kitAvailable on requestTeva PharmaceuticalsUS FDA4 packs Cold chain
- Yuflyma kitAvailable on requestCelltrionUS FDA5 packs Cold chain
Other strengths and forms of Adalimumab
Clinical summary
Adalimumab is a tumor necrosis factor blocker indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. MedsAcross supplies Adalimumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AdalimumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Humira prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Humira: European public assessment report (EPAR) · European Medicines Agency
- Amgevita: European public assessment report (EPAR) · European Medicines Agency
Need Abrilada kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.